Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer
21/07/2026 12:33
BRIEF-Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer July 21 (Reuters) - Plus Therapeutics Inc PSTV.O:
PLUS THERAPEUTICS SECURES REGIONAL COVERAGE AGREEMENT WITH MEDICAL MUTUAL FOR CNSIDE® CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER
PLUS THERAPEUTICS - TO CHANGE NAME TO CERENOME, AND TICKER TO CNSY ON AUGUST 3, 2026
Source text: ID:nGNX47VDfb
Further company coverage: PSTV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer